Antengene Announces Upcoming Presentations at the 2022 Society for Immunotherapy of Cancer Annual Meeting

- **Oral presentation** highlights preclinical data of **ATG-031, an in-house discovered anti-CD24 monoclonal antibody**

- **Three poster presentations** showcase preclinical data of **ATG-101, a PD-L1/4-1BB bispecific antibody developed in-house, ATG-018, an ATR inhibitor discovered in-house, and ATG-027, a B7H3/PD-L1 bispecific antibody discovered in-house**

- **Antengene has global rights to these pipeline assets**

At the 37th Society for Immunotherapy of Cancer Annual Meeting (SITC 2022), set to take place on November 8-12, 2022, in Boston, Massachusetts (United States), via in person/virtual attendance, Antengene will release data from preclinical studies of four pipeline assets, ATG-031, ATG-101, ATG-018, and ATG-027, in one oral presentation and three poster presentations. As the world’s largest and most anticipated gathering in the field of immuno-
oncology, the SITC Annual Meeting is designed to promote scientific exchanges and cooperation for improving treatment outcomes for cancer patients.

**Details of the oral presentation are shown as below:**

**Title:** ATG-031, a first-in-class anti-CD24 antibody, showed potent preclinical anti-tumor efficacy by blocking “don’t-eat-me” signal

**Abstract#:** 482

**Date:** November 11, 2022

**Time:** 5:20 PM – 5:35 PM (Eastern Time)

   (6:20 AM – 6:35 AM Beijing Time, November 12, 2022)

**Presenter:** Dr. Jay Mei, Antengene

**First Author:** Dr. Peng Chen, Antengene

**Corresponding Authors:** Dr. Bo Shan, Dr. Bing Hou, Antengene

**Details of those three poster presentations are shown below. All posters will be presented at:**

**Title:** ATG-101, a tetravalent PD-L1×4-1BB BsAb, demonstrates potent
in vivo anti-tumor efficacy in ICI-resistant or refractory mouse tumor models

Abstract#: 1150

Date: November 10, 2022

Presenter: Dr. Bing Hou, Antengene

First Author: Dr. Wenhui Yu, Antengene

Corresponding Authors: Dr. Bo Shan, Dr. Bing Hou, Antengene

Title: Discovery of blood pharmacodynamic biomarkers for ATR inhibitors

Abstract#: 76

Date: November 10, 2022

Presenter: Dr. Bin Jiang, Antengene

First Author: Dr. Ya Kong, Antengene

Corresponding Authors: Dr. Shan Bo, Dr. Bing Hou, Antengene

Title: ATG-027, a first-in-class B7-H3/PD-L1 bispecific antibody, shows potent T cell activation capability and in vivo anti-tumor efficacy

Abstract#: 1397

Date: November 10, 2022
**Presenter:** Dr. Linjie Tian, Antengene  
**First Author:** Dr. Wenhui Yu, Antengene  
**Corresponding Authors:** Dr. Bo Shan, Dr. Bing Hou, Antengene

**About Antengene**

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "**Treating Patients Beyond Borders**".

Since 2017, Antengene has built a broad and expanding pipeline of 15 clinical and preclinical assets, of which 10 are global rights assets, and 5 came with rights for Asia Pacific markets including the Greater China region. To date, Antengene has obtained 24 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 6 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor), already approved in mainland China, South Korea, Singapore and Australia.
Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled “Risk Factors” in our periodic reports filed with the Hong Kong Stock Exchange and the other risks and uncertainties described in the Company’s Annual Report for year-end December 31, 2021, and subsequent filings with the Hong Kong Stock Exchange.